Cytogel LLC, based in Troy, NY, is a clinical stage bio-pharmaceutical company focused on revolutionizing pain management through the development of novel endomorphin-based drug candidates. Their groundbreaking approach aims to provide potent and safe pain relief while minimizing the limitations associated with traditional therapies.
With their lead candidate, CYT-1010, entering Phase 2 human trials, Cytogel is dedicated to offering a transformative solution for moderate to severe pain, showcasing reduced addiction potential and minimal risk of respiratory depression compared to existing treatments. Through their innovative research and development efforts, Cytogel is poised to make a significant impact on pain treatment for patients and healthcare providers alike.
Generated from the website